Guidance notes for expressions of interest for mobile ECG devices to help detect Atrial Fibrillation

Applicants should consider how mobile ECGs will be incorporated into the patient pathway and how onward referral and further investigation (e.g. 12 lead ECG) and treatment (anticoagulation or other treatments) for anyone identified with ‘possible atrial fibrillation’ will be initiated in a timely manner.

We recognise the importance of regular pulse rhythm checks, and that a normal pulse rhythm at a single point in time does not guarantee that patients do not have paroxysmal (intermittent) atrial fibrillation, or that they will never develop atrial fibrillation during their lifetime. Applicants should consider how this information will be conveyed to individuals receiving a pulse rhythm check with a mobile ECG device.

Applications are welcomed from a variety of settings and clinical disciplines. We encourage applications from Clinical Commissioning Groups for their regions.

Key selection criteria:

1. Applicants have considered how mobile ECGs will be incorporated into the patient pathway
2. Applicants plan to use each device with at least 25 people per week
3. Applicants agree to contribute to the national evaluation and activity reporting for the programme.

Applications demonstrating the potential for high daily usage of devices will be considered favorably.

Please see the Eastern AHSN Mobile ECG Guidance Document.

Further information:

Please see the Atrial Fibrillation Toolkit for further information on mobile ECGs

Please see further information on the Alivecor mobile ECG device including the previous research and settings where the device has been deployed here

For National Institute for Health and Care Excellence (NICE) Medtech innovation briefing on the Alivecor mobile ECG device please click here

For NHS England information on high value interventions for atrial fibrillation please see further information here.